Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent
- PMID: 12133275
- DOI: 10.1089/104303402320139005
Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent
Abstract
The study was designed to evaluate whether TAPET-CD, an attenuated strain of Salmonella typhimurium expressing Escherichia coli cytosine deaminase (CD), was capable of converting nontoxic 5-fluorocytosine (5-FC) to the active antitumor agent 5-fluorouracil (5-FU). The antitumor effect of TAPET-CD plus 5-FC against subcutaneously implanted colon tumors was also evaluated. TAPET-CD was given to tumor-bearing mice by a single bolus intravenous administration followed with 5-FC by intraperitoneal administration. TAPET-CD accumulated in tumors at levels 1000-fold higher than that in normal tissues and high levels of 5-FU were detected in tumors in mice treated with both TAPET-CD and 5-FC. No 5-FU could be detected in normal tissues. Inhibition of tumor growth was observed in mice treated with either TAPET-CD alone or TAPET-CD in combination with 5-FC (TAPET-CD/5-FC), but not with 5-FC alone. TAPET-CD/5-FC inhibited tumor growth by 88%-96%, compared to TAPET-CD alone, which inhibited tumor growth by 38%-79%. These data suggest that tumor-targeting Salmonella could be used to deliver prodrug-converting enzyme selectively to tumors and produced anti-tumor effects when the corresponding prodrug was also given.
Similar articles
-
A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.Hum Gene Ther. 2001 Aug 10;12(12):1594-6. Hum Gene Ther. 2001. PMID: 11529249 Clinical Trial.
-
Evaluation of the acute and subchronic toxic effects in mice, rats, and monkeys of the genetically engineered and Escherichia coli cytosine deaminase gene-incorporated Salmonella strain, TAPET-CD, being developed as an antitumor agent.Int J Toxicol. 2001 Jul-Aug;20(4):207-17. doi: 10.1080/109158101750408037. Int J Toxicol. 2001. PMID: 11563416
-
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.Cancer Gene Ther. 2003 Oct;10(10):737-44. doi: 10.1038/sj.cgt.7700634. Cancer Gene Ther. 2003. PMID: 14502226 Clinical Trial.
-
Use of bacteria as anticancer agents.Expert Opin Biol Ther. 2001 Mar;1(2):291-300. doi: 10.1517/14712598.1.2.291. Expert Opin Biol Ther. 2001. PMID: 11727536 Review.
-
Genetically engineered Salmonella Typhimurium: Recent advances in cancer therapy.Cancer Lett. 2019 Apr 28;448:168-181. doi: 10.1016/j.canlet.2019.01.037. Epub 2019 Feb 10. Cancer Lett. 2019. PMID: 30753837 Review.
Cited by
-
Autonomous bacterial nanoswimmers target cancer.J Control Release. 2017 Jul 10;257:68-75. doi: 10.1016/j.jconrel.2016.10.006. Epub 2016 Oct 12. J Control Release. 2017. PMID: 27744036 Free PMC article.
-
Hypoxia-targeting bacteria in cancer therapy.Semin Cancer Biol. 2024 May;100:39-48. doi: 10.1016/j.semcancer.2024.03.003. Epub 2024 Mar 29. Semin Cancer Biol. 2024. PMID: 38554791 Free PMC article. Review.
-
Leveraging dysregulated tumor metabolism for targeting anticancer bacteria.Sci Adv. 2025 Jun 13;11(24):eads1630. doi: 10.1126/sciadv.ads1630. Epub 2025 Jun 13. Sci Adv. 2025. PMID: 40512849 Free PMC article.
-
Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression.Br J Cancer. 2007 Mar 12;96(5):758-61. doi: 10.1038/sj.bjc.6603624. Epub 2007 Feb 20. Br J Cancer. 2007. PMID: 17311022 Free PMC article.
-
Advances on Non-Genetic Cell Membrane Engineering for Biomedical Applications.Polymers (Basel). 2019 Dec 5;11(12):2017. doi: 10.3390/polym11122017. Polymers (Basel). 2019. PMID: 31817418 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources